FDA Bans Fake Drug Importer Sanjay Kumar for Five Years
Published Date: 9/23/2026
Notice
Summary
Sanjay Kumar is banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime involving fake goods. He didn’t respond to the FDA’s notice, so the ban starts on September 23, 2026. He can apply to end the ban anytime, but must follow special rules to keep info private.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Five-year ban on importing drugs
Sanjay Kumar is barred for 5 years from importing or offering for import any drug into the United States, effective September 23, 2026. The FDA based the order on his March 5, 2026 federal felony conviction for conspiracy to traffic in counterfeit goods (18 U.S.C. 2320), including sales of counterfeit Keytruda.
Prohibition on others importing with his help
During the 5-year debarment period beginning September 23, 2026, importing or offering for import any drug 'by, with the assistance of, or at the direction of' Sanjay Kumar is a prohibited act under 21 U.S.C. 331(cc). Businesses or people who import drugs with his assistance would be engaging in a prohibited act while the debarment is in effect.
Right to apply for early termination and confidentiality rules
Mr. Kumar may apply at any time to terminate his debarment under section 306(d)(1) of the FD&C Act. The FDA explains how to submit such an application (electronically via regulations.gov or in paper) and describes procedures to keep specified information confidential when submitted as a paper 'Confidential Submission.'
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19349, Nonclinical Testing Terminology
The FDA wants to update its rules by swapping out the word “animal” tests for “nonclinical” tests to better reflect modern science. This change affects drug safety testing rules, encourages new testing methods that might use fewer animals, and doesn’t add any new costs or requirements. Anyone interested can comment on these changes until December 7, 2026.
2026-19350, Nonclinical Testing Terminology
The FDA is updating its rules to replace the words “animal” tests with “nonclinical” tests, making room for new, smarter ways to check drug safety without relying only on animal testing. This change affects drug makers and researchers but won’t add new costs or requirements. The rule kicks in on February 4, 2027, and comments are open until December 7, 2026.
Previous / Next Documents
Previous: 2026-19415, Notice of OFAC Sanctions Action
The U.S. Treasury’s OFAC has lifted sanctions on certain Eritrean individuals and groups linked to Ethiopia, removing them from the blocked list as of September 18, 2026. This means their property in the U.S. is no longer frozen, signaling a big change in how these people and organizations can do business. The move follows the end of a national emergency that started in 2021.
Next: 2026-19420, Fruit Crops; Notice of Request for Extension and Revision of a Currently Approved Information Collection
The USDA’s Agricultural Marketing Service wants to keep collecting info about fruit crops and make some updates to how they do it. This affects fruit growers and businesses involved in federal marketing orders. They’re asking for your thoughts by November 23, 2026, and this helps keep fruit marketing smooth without extra costs.